Puma Biotechnology, Inc.
PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabinā¦ read more
Healthcare
Biotechnology
14 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.93
Price+0.51%
$0.04
1Y
Price
Market Cap
$403.633m
Small
Price/Earnings 3y Avg5y Avg
13x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+24.7%
EBITDA Margin+16.2%
Net Profit Margin+17.7%
Free Cash Flow Margin+24.7%
EBITDA Margin+16.2%
Net Profit Margin+17.7%
Free Cash Flow MarginRevenue
$227.178m
-8.0%
1y CAGR-2.3%
3y CAGR-4.2%
5y CAGREarnings
$24.384m
+22.1%
1y CAGR+359837.5%
3y CAGR+269903.1%
5y CAGREPS
$0.48
+19.4%
1y CAGR+735.7%
3y CAGR+577.5%
5y CAGRBook Value
$128.416m
$192.699m
Assets$64.283m
Liabilities$15.954m
DebtDebt to Assets
8.3%
0.8x
Debt to EBITDAFree Cash Flow
$53.596m
+10.3%
1y CAGR+114.6%
3y CAGR+33.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company